ULTRAGENYX PHARMACEUTICAL INC. Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
ULTRAGENYX PHARMACEUTICAL INC. (RARE) had Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount of $232.00 million as of 2025-12-31, per its 10-K filed 2026-02-18.
Financial Statements › Notes › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions · last filed 2026-02-18
- 2025-12-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $232.00M.
- 2024-12-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $256.80M.
- 2023-12-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $219.80M.
- 2022-12-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $229.40M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount |
|---|---|
| 2025-12-31 | $232.00M 10-K · filed 2026-02-18 |
| 2024-12-31 | $256.80M 10-K · filed 2025-02-19 |
| 2023-12-31 | $219.80M 10-K · filed 2024-02-21 |
| 2022-12-31 | $229.40M 10-K · filed 2023-02-17 |
| 2021-12-31 | $200.00M 10-K · filed 2022-02-15 |
| 2020-12-31 | $155.60M 10-K · filed 2021-02-12 |
| 2019-12-31 | $133.00M 10-K · filed 2020-02-14 |
| 2018-12-31 | $131.00M 10-K · filed 2019-02-20 |
| 2017-12-31 | $165.30M 10-K · filed 2018-02-21 |
| 2016-12-31 | $136.50M 10-K · filed 2017-02-17 |
| 2015-12-31 | $102.80M 10-K · filed 2016-02-26 |
| 2014-12-31 | $22.50M 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |